The 2021 ASCO Annual Meeting offered a variety of advancements in the treatment and detection of genitourinary cancers. For prostate cancer (PCa), matched tumour-normal tissue sequencing was shown to be the ideal standard of care (SOC) in de novo high-risk PCa patients. The addition of immune checkpoint inhibitors (ICI) to the SOC was found to be highly effective in muscle-invasive bladder cancer, with enfor-tumab vedotin (EV) continuing to show efficacy in urothelial carcinoma in a post-ICI advanced/ metastatic setting. Finally, the combination of ICI and tyrosine kinase inhibitors (TKIs) as first-line therapy for both non-clear cell and clear cell renal cell carcinoma (non-cc/ccRCC) displays a clear survival benefit, with this efficacy extending into the second-line treatment of patients with metastatic non-ccRCC who have previously received ICIs. The most important headline presentations relating to genitourinary cancers will be discussed in this congress highlights article.
(BELG J MED ONCOL 2021;15(5):256-63)